

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. If you are in any doubt as to any matter referred to in this document or as to the action you should take, you should consult an independent financial adviser authorised under the Financial Services and Markets Act 2000 (as amended) if you are in the United Kingdom, or another appropriately authorised independent financial adviser if you are in a territory outside the United Kingdom, without delay.

If you have sold or otherwise transferred all of your Ordinary Shares, please send this document at once to the purchaser or transferee or to the bank, stockbroker or other agent through whom or by whom the sale or transfer was made, for delivery to the purchaser or transferee. However, the distribution of this document in jurisdictions other than the United Kingdom may be restricted by law and therefore persons into whose possession this document comes should inform themselves about and observe those restrictions. Any failure to comply with any of those restrictions may constitute a violation of the securities laws of any such jurisdiction.

BB HEALTHCARE TRUST PLC

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

Proposals to grant authority to allot Ordinary Shares on a non-pre-emptive basis

and

Notice of General Meeting

Notice of a general meeting of the Company to be held at Sanne Group, 6th Floor, 125 London Wall, Barbican, London EC2Y 5AS on 11 January 2022 at 10.00 a.m. is set out at the end of this document.

Proxies may be submitted electronically using Link Group's Signal Shares share portal service at www.signalshares.com or in hard copy form if you request a hard copy form of proxy from the Company's registrar, Link Group. In order to be valid, proxy appointments must be submitted using Link Group's Signal Shares share portal service or in hard copy form to Link Group at 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL, in each case, by no later than 10.00 a.m. on 7 January 2022 or 48 hours before any adjourned meeting.

If you require a hard copy form of proxy (or assistance with how to complete, sign and return it) or assistance in submitting your proxy appointment electronically, please call Link Group on +44(0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales.

If you hold your Ordinary Shares in uncertificated form (i.e. in CREST) you may appoint a proxy for the General Meeting by completing and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual issued by Euroclear so that it is received by the registrar (under CREST Participation ID RA10) by no later than 10.00 a.m. on 7 January 2022. The time of receipt will be taken to be the time from which the registrar is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

TABLE OF CONTENTS

| | |
|----------------------------------|---|
| DEFINITIONS | 3 |
| LETTER FROM THE CHAIRMAN | 4 |
| NOTICE OF GENERAL MEETING | 8 |

DEFINITIONS

In this document the words and expressions listed below have the meanings set out opposite them, except where the context otherwise requires:

| | |
|---|--|
| “Articles” | the articles of association of the Company in force at the date of this document |
| “Company” | BB Healthcare Trust plc |
| “CREST” | the relevant system as defined in the CREST Regulations in respect of which Euroclear is the operator (as defined in the CREST Regulations) in accordance with which securities may be held in uncertificated form |
| “CREST Regulations” | the Uncertificated Securities Regulations 2001 (SI 2001 No. 2001/3755), as amended |
| “Directors” or “Board” | the board of directors of the Company |
| “Euroclear” | Euroclear UK & International Limited |
| “FCA” | the UK Financial Conduct Authority |
| “General Meeting” | the general meeting of the Company to be held at Sanne Group, 6th Floor, 125 London Wall, Barbican, London, EC2Y 5AS on 11 January 2022 at 10.00 a.m. for the purpose of approving the Resolutions |
| “Latest Practicable Date” | 10 December 2021, being the latest practicable date prior to the date of this document for ascertaining information contained herein |
| “London Stock Exchange” | London Stock Exchange plc |
| “Net Asset Value” | the value of the assets of the Company less its liabilities, determined in accordance with the accounting principles adopted by the Company from time to time |
| “Net Asset Value per Ordinary Share” | the Net Asset Value attributable to the Ordinary Shares divided by the number of Ordinary Shares in issue (excluding any Ordinary Shares held in treasury) |
| “Official List” | the official list maintained by the FCA |
| “Ordinary Shares” | ordinary redeemable shares of £0.01 each in the capital of the Company |
| “Proposals” | the proposals described and defined in this document |
| “Resolutions” | the resolutions to be proposed at the General Meeting in connection with the Proposals |
| “Shareholder” | a holder of Ordinary Shares |

LETTER FROM THE CHAIRMAN

BB HEALTHCARE TRUST PLC

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

Directors:

Randeep Grewal (*Chairman*)
Professor Justin Stebbing
Josephine Dixon
Paul Southgate
Professor Antony Young, OBE
Katharine Bolsover

Registered Office:

6th Floor,
125 London Wall
London
EC2Y 5AS

10 December 2021

To Shareholders

Dear Sir or Madam

1 Introduction

At the annual general meeting of the Company held on 23 April 2021, the Directors were granted authority to allot up to 50,734,545 Ordinary Shares on a non-pre-emptive basis. As at the Latest Practicable Date, 44,616,598 Ordinary Shares have already been issued pursuant to this authority. The Board is now seeking Shareholder authority to allot up to a further 56,563,590 new Ordinary Shares on a non-pre-emptive basis, to enable the Company to carry out a series of placings or tap issues, providing the Company with the ability to issue new Ordinary Shares over a period of time to meet investor demand and help with managing the premium at which the Ordinary Shares typically trade.

The Directors are convening a General Meeting to seek the approval of Shareholders for the Proposals. The General Meeting will be held at Sanne Group, 6th Floor, 125 London Wall, Barbican, London, EC2Y 5AS on 11 January 2022 at 10.00 a.m. The formal notice convening the General Meeting is set out at the end of this document.

The Company continues to monitor the COVID-19 situation, including UK Government legislation and guidance, and will continue to do so in the lead up to the General Meeting. The health of our Shareholders, Directors and stakeholders is extremely important to us. Whilst as at the date of this document there are no restrictions on public meetings, there is no guarantee that things will not change between this date and the date of the General Meeting.

In the event that the Company is forced, due to the reimplementing of COVID-19 restrictions, to hold the meeting as a closed meeting, or limit the numbers of people able to attend, a further announcement will be made.

The Resolutions that will be put to Shareholders at the General Meeting are to:

- authorise the allotment of up to 56,563,590 Ordinary Shares; and
- disapply statutory pre-emption rights otherwise applicable to the allotment of Ordinary Shares such that Ordinary Shares do not first have to be offered to Shareholders in proportion to their holdings of Ordinary Shares, (together, the “**Proposals**”).

The purpose of this document is to provide Shareholders with details of the Proposals and to set out the reasons why the Directors are recommending that Shareholders vote in favour of the Resolutions.

2 Details of the Proposals

The Directors intend that the Company be permitted to continue to issue Ordinary Shares to satisfy market demand. The price at which any new Ordinary Shares will be issued to satisfy market demand will be not less than the prevailing Net Asset Value (cum-income) per Ordinary Share at the time of issue plus a premium to cover the expenses of such issue.

If the Resolutions are passed, the Company will be permitted to issue up to 56,563,590 Ordinary Shares (representing approximately 10 per cent. of the issued share capital (excluding treasury shares) of the Company as at the Latest Practicable Date) to investors without first having to offer them, *pro rata*, to existing Shareholders. These new authorities are in addition to the residual authorities to disapply pre-emption rights on the issue of new Ordinary Shares taken at the Company's last annual general meeting. At the Latest Practicable Date, the Company had authority to issue up to 6,217,947 new Ordinary Shares on a non-pre-emptive basis pursuant to these residual authorities.

Applications will be made to the FCA and the London Stock Exchange for all of the new Ordinary Shares to be issued to be admitted to the premium segment of the Official List and to trading on the London Stock Exchange's main market for listed securities.

The new Ordinary Shares will rank *pari passu* with the Ordinary Shares then in issue (save for any dividends or other distributions declared, made or paid on the Ordinary Shares by reference to a record date prior to the allotment of the new Ordinary Shares). No fractions of Ordinary Shares will be issued.

The authorities conferred by the Resolutions, if passed, will lapse at the annual general meeting of the Company to be held in 2022.

3 Treasury shares

No Ordinary Shares were held in treasury at the date of this document.

4 CREST

The Ordinary Shares will be issued in registered form. CREST is a paperless settlement procedure enabling securities to be evidenced otherwise than by a certificate and transferred otherwise than by written instrument. The Articles permit the holding of Ordinary Shares under the CREST system. Settlement of transactions in the Ordinary Shares may take place within the CREST system if any Shareholder so wishes. CREST is a voluntary system and Shareholders who wish to receive and retain share certificates will be able to do so. Shareholders applying for Ordinary Shares may elect to receive Ordinary Shares in uncertificated form if such investor is a system-member (as defined in the CREST Regulations) in relation to CREST.

5 Benefits of the Proposals

The Directors believe that the Proposals will have the following benefits for Shareholders:

- enable the Company to continue to take advantage of opportunities to make further investments in accordance with its investment objective and policy;
- increase the market capitalisation of the Company, helping to make the Company attractive to a wider investor base;
- a greater number of Ordinary Shares in issue should improve liquidity in the secondary market for the Ordinary Shares and make the Ordinary Shares more attractive to a wider range of investors; and
- grow the Company, thereby spreading the Company's fixed running costs across a larger equity capital base which should reduce the level of ongoing expenses per Ordinary Share.

The price at which Ordinary Shares are issued to satisfy market demand will be not less than the prevailing Net Asset Value (cum-income) per Ordinary Share at the time of issue plus a premium to cover the expenses of such issue, therefore Shareholders will not suffer any dilution to the Net Asset Value (cum-income) per Ordinary Share as a result of any such issue.

6 Considerations associated with the Proposals

Any issue of Ordinary Shares on a non-pre-emptive basis will result in a dilution of Shareholders' ownership and voting interests in the Company.

7 General Meeting

The General Meeting has been convened for 10.00 a.m. on 11 January 2022.

Resolutions 1 and 2, which will be proposed as an ordinary resolution and a special resolution respectively, will, if passed, give the Directors the authority to allot up to 56,563,590 Ordinary Shares on a non-pre-emptive basis.

An ordinary resolution requires a simple majority of members entitled to vote and present in person or by proxy to vote in favour in order for it to be passed. A special resolution requires a majority of at least 75 per cent. of members entitled to vote and present in person or by proxy to vote in favour in order for it to be passed.

All Shareholders are entitled to vote at the General Meeting. In accordance with the Articles, all Shareholders present in person or by proxy shall upon a show of hands have one vote and upon a poll shall have one vote in respect of each Ordinary Share held. In order to ensure that a quorum is present at the General Meeting, it is necessary for two Shareholders ("**qualifying persons**") entitled to vote to be present, whether in person or by proxy (or, if a corporation, by a representative).

The formal notice convening the General Meeting is set out at the end of this document.

8 Action to be taken in respect of the General Meeting

Please submit your vote by proxy electronically using Link Group's Signal Shares share portal service at www.signalshares.com or in hard copy form if you request a hard copy form of proxy from the Company's registrar, Link Group. In order to be valid, proxy appointments must be submitted using Link Group's Signal Shares share portal service or in hard copy form to Link Group at 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL, in each case, by no later than 10.00 a.m. on 7 January 2022 or 48 hours before any adjourned meeting.

If you require a hard copy form of proxy (or assistance with how to complete, sign and return it) or assistance in submitting your proxy appointment electronically, please call Link Group on +44 (0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m. Monday to Friday, excluding public holidays in England and Wales.

If you hold your Ordinary Shares in uncertificated form (i.e. in CREST), you may appoint a proxy for the General Meeting by completing and transmitting a CREST Proxy Instruction in accordance with the procedures set out in the CREST Manual issued by Euroclear so that it is received by the registrar (under CREST Participation ID RA10) by no later than 10.00 a.m. on 7 January 2022. The time of receipt will be taken to be the time from which the registrar is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST.

Shareholders are requested to appoint a proxy whether or not they wish to attend the General Meeting. The appointment of a proxy will not prevent Shareholders from attending the General Meeting and voting in person should they so wish.

9 Recommendation

The Board considers that the Proposals are in the best interests of the Company and its Shareholders as a whole. Accordingly the Board unanimously recommends that Shareholders vote in favour of the Resolutions to be proposed at the General Meeting. The Directors intend to vote in favour of the Resolutions in respect of their holdings of Ordinary Shares, amounting to 333,181 Ordinary Shares in aggregate (representing approximately 0.059 per cent. of the issued share capital of the Company as at the date of this document).

10 Questions

Should a Shareholder have any questions about the Proposals, the Board asks that they email shareholder_questions@bbhealthcaretrust.co.uk or alternatively, contact the Company's Joint Brokers; Alvarium Securities or J.P. Morgan Cazenove by email at mark@alvariumsecurities.com or william.simmonds@jpmorgancazenove.com.

Yours faithfully

Randeep Grewal
(Chairman)

BB HEALTHCARE TRUST PLC

(Incorporated in England and Wales with company number 10415235 and registered as an investment company under section 833 of the Companies Act 2006)

NOTICE OF GENERAL MEETING

Notice is hereby given that a General Meeting of BB Healthcare Trust plc (the “**Company**”) will be held at Sanne Group, 6th Floor, 125 London Wall, Barbican, London, EC2Y 5AS on 11 January 2022 at 10.00 a.m. to consider and, if thought fit, approve the following resolutions, in the case of Resolution 1 as an ordinary resolution and in the case of Resolution 2 as a special resolution:

ORDINARY RESOLUTION

- 1 **THAT** the directors of the Company (the “**Directors**”) be and are hereby generally and unconditionally authorised, pursuant to and in accordance with section 551 of the Companies Act 2006 (the “**Act**”), and in addition to any authority previously conferred upon the Directors pursuant to Section 551 of the Act, to exercise all the powers of the Company to allot ordinary shares of one penny each in the capital of the Company (“**Ordinary Shares**”), up to an aggregate nominal amount of £565,635.90 such authority to expire at the conclusion of the annual general meeting of the Company to be held in 2022 (unless previously revoked or varied by the Company in general meeting), save that the Company may, at any time prior to the expiry of such authority, make an offer or enter into an agreement which would or might require Ordinary Shares to be allotted and the Directors may allot Ordinary Shares in pursuance of such an offer or agreement as if the authority conferred hereby had not expired.

SPECIAL RESOLUTION

- 2 **THAT**, subject to the passing of Resolution 1 above and in addition to any power previously conferred upon the Directors pursuant to sections 570 and 573 of the Act, the Directors be and are hereby empowered, pursuant to sections 570 to 573 of the Act, to allot Ordinary Shares for cash pursuant to the authority referred to in Resolution 1 above and to sell Ordinary Shares from treasury for cash as if section 561 of the Act did not apply to any such allotment or sale, provided that this authority shall be limited to the allotment or sale of Ordinary Shares up to an aggregate nominal amount of £565,635.90 and shall expire at the conclusion of the annual general meeting of the Company to be held in 2022 (unless previously revoked or varied by the Company in general meeting), save that the Company may, at any time prior to the expiry of such power, make an offer or enter into an agreement which would or might require Ordinary Shares to be allotted or sold from treasury after the expiry of such power, and the Directors may allot Ordinary Shares or sell Ordinary Shares from treasury in pursuance of such an offer or agreement as if such power had not expired.

By Order of the Board

PraxisIFM Fund Services (UK) Limited
Company Secretary

Registered Office:

6th Floor,
125 London Wall
London
EC2Y 5AS

Dated 10 December 2021

Notes

1 Website address

Information regarding the meeting, including the information required by section 311A of the Companies Act 2006, is available from www.bbhealthcaretrust.com.

2 Entitlement to attend and vote

Only those holders of Ordinary Shares registered in the Company's register of members at 6.00 p.m. on 7 January 2022 or, if this meeting is adjourned, at close of business on the day two days prior to the adjourned meeting, shall be entitled to attend and vote at the meeting.

The Company continues to monitor the COVID-19 situation, including UK Government legislation and guidance, and will continue to do so in the lead up to the General Meeting. The health of our Shareholders, Directors and stakeholders is extremely important to us. Whilst as at the date of this document there are no restrictions on public meetings, there is no guarantee that things will not change between this date and the date of the General Meeting.

In the event that the Company is forced, due to the reimplementation of COVID-19 restrictions, to hold the meeting as a closed meeting, or limit the numbers of people able to attend, a further announcement will be made.

3 Appointment of proxies

If you are a member of the Company at the time set out in note 2 above, you are entitled to appoint a proxy to exercise all or any of your rights to attend, speak and vote at the meeting. You can appoint a proxy using only the procedures set out in these notes and the notes to the proxy form.

A proxy does not need to be a member of the Company but must attend the meeting to represent you. If you wish your proxy to speak on your behalf at the meeting you will need to appoint your own choice of proxy (not the Chairman) and give your instructions directly to them.

You may appoint more than one proxy provided each proxy is appointed to exercise rights attached to different shares. You may not appoint more than one proxy to exercise rights attached to any one share. To appoint more than one proxy, please indicate on your proxy submission how many shares it relates to.

A vote withheld is not a vote in law, which means that the vote will not be counted in the calculation of votes for or against the Resolution. If no voting indication is given, your proxy will vote or abstain from voting at his or her discretion. Your proxy will vote (or abstain from voting) as he or she thinks fit in relation to any other matter which is put before the meeting.

4 Appointment of proxy using hard copy form

A hard copy form of proxy has not been sent to you but you can request one directly from the registrars, Link Group's general helpline team +44 (0)371 664 0300. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales. Alternatively, you can request a hard copy form of proxy via email at shareholderenquiries@linkgroup.co.uk or via postal address at Link Group, 10th Floor, Central Square, 29 Wellington Street, Leeds LS1 4DL. In the case of a member which is a company, the proxy form must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the proxy form is signed (or a duly certified copy of such power or authority) must be included with the proxy form.

5 Appointment of a proxy online

You may submit your proxy electronically using the Share Portal service at www.signalshares.com. Shareholders can use this service to vote or appoint a proxy online. The same voting deadline of 48 hours before the time of the meeting applies. Shareholders will need to use the unique personal identification Investor Code ("IVC") printed on your share certificate. If you need help with voting online, please contact Link Group's portal team on 0371 664 0391 or via email at shareholderenquiries@linkgroup.co.uk. Calls are charged at the standard geographic rate and will vary by provider. Calls from outside the UK will be charged at the applicable international rate. Lines are open 9.00 a.m. to 5.30 p.m., Monday to Friday, excluding public holidays in England and Wales.

If you are an institutional investor, you may be able to appoint a proxy electronically via the Proximity platform, a process which has been agreed by the Company and approved by the Registrar. For further information regarding Proximity, please go to www.proximity.io. Your proxy must be lodged by 10.00 a.m. on 7 January 2022 in order to be considered valid. Before you can appoint a proxy via this process you will need to have agreed to Proximity's associated terms and conditions. It is important that you read these carefully as you will be bound by them and they will govern the electronic appointment of your proxy.

6 Appointment of proxy through CREST

CREST members who wish to appoint a proxy or proxies through the CREST electronic proxy appointment service may do so for the meeting to be held on the above date and any adjournment(s) thereof by using the procedures described in the CREST Manual. CREST Personal Members or other CREST sponsored members, and those CREST members who have appointed a voting service provider(s), should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

In order for a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a "CREST Proxy Instruction") must be properly authenticated in accordance with Euroclear UK & International Limited's specifications and must contain the information required for such instructions, as described in the CREST Manual. The message, regardless of whether it constitutes the appointment of a proxy or an amendment to the instruction given to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the Company's agent (ID: RA10) by the latest time(s) for receipt of proxy appointments specified below. For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the Company's agent is

able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear UK & International Limited does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions. It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST personal member or sponsored member or has appointed a voting service provider(s), to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The Company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.

7 Appointment of proxy by joint members

In the case of joint holders, where more than one of the joint holders purports to appoint a proxy, only the appointment submitted by the most senior holder will be accepted. Seniority is determined by the order in which the names of the joint holders appear in the Company's register of members in respect of the joint holding, the first-named being the most senior.

8 Changing proxy instructions

To change your proxy instructions simply submit a new proxy appointment using the methods set out above. Note that the cut-off times for receipt of proxy appointments (see above) also apply in relation to amended instructions; any amended proxy appointment received after the relevant cut-off time will be disregarded. Where you have appointed a proxy using a hard copy proxy form and would like to change the instructions using another hard copy proxy form, please contact Link Group as per the communication methods shown in note 4. If you submit more than one valid proxy appointment, the appointment received last before the latest time for the receipt of proxies will take precedence.

9 Termination of proxy appointments

In order to revoke a proxy instruction, you will need to inform the Company by sending a signed hard copy notice clearly stating your intention to revoke your proxy appointment to Link Group, at the address shown in note 4. In the case of a member which is a company, the revocation notice must be executed under its common seal or signed on its behalf by an officer of the company or an attorney for the company. Any power of attorney or any other authority under which the revocation notice is signed, or a duly certified copy of such power or authority, must be included with the revocation notice. The revocation notice must be received by Link Group no later than 48 hours before the meeting.

Completion of a proxy will not preclude you from attending the meeting and voting in person if you so wish.

10 Nominated persons

If you are a person who has been nominated under section 146 of the Companies Act 2006 to enjoy information rights:

- (a) You may have a right under an agreement between you and the member of the Company who has nominated you to have information rights ("**Relevant Member**") to be appointed or to have someone else appointed as a proxy for the meeting.
- (b) If you either do not have such a right or if you have such a right but do not wish to exercise it, you may have a right under an agreement between you and the Relevant Member to give instructions to the Relevant Member as to the exercise of voting rights.
- (c) Your main point of contact in terms of your investment in the Company remains the Relevant Member (or, perhaps, your custodian or broker) and you should continue to contact them (and not the Company) regarding any changes or queries relating to your personal details and your interest in the Company (including any administrative matters). The only exception to this is where the Company expressly requests a response from you.

If you are not a member of the Company but you have been nominated by a member of the Company to enjoy information rights, you do not have a right to appoint any proxies.

11 Questions at the meeting

Under section 319A of the Companies Act 2006, the Company must answer any question you ask relating to the business being dealt with at the meeting unless:

- (a) answering the question would interfere unduly with the preparation for the meeting or involve the disclosure of confidential information;
- (b) the answer has already been given on a website in the form of an answer to a question; or
- (c) it is undesirable in the interests of the Company or the good order of the meeting that the question be answered.

12 Issued shares and total voting rights

As at the date of this notice, the total number of shares in issue is 565,635,904 Ordinary Shares of 1p each. The total number of Ordinary Shares with voting rights is 565,635,904. On a vote by a show of hands, every holder of Ordinary Shares who (being an individual) is present in person, by proxy or (being a corporation) is present by a duly authorised representative, not being himself a member, shall have one vote. On a poll every holder of Ordinary Shares who is present in person or by proxy shall have one vote for every Ordinary Share held by him.

13 Communication

Except as provided above, members who have general queries about the meeting should use the following means of communication (no other methods of communication will be accepted):

- (a) calling Link Group's shareholder helpline (lines are open from 9.00 a.m. to 5.30 p.m. Monday to Friday, excluding public holidays):
 - (i) From UK: 0371 664 0300 (calls cost 12p per minute plus network extras);
 - (ii) From Overseas: +44 371 664 0300 (calls from outside the UK are charged at applicable international rates); or
- (b) in writing to Link Group.

You may not use any electronic address provided either in this notice of meeting or in any related documents (including the form of proxy for this meeting) to communicate with the Company for any purposes other than those expressly stated.

